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The human immunodeficiency virus (HIV) burden in women continues to increase, and
heterosexual contact is now the most common route of infection worldwide. Effective
protection of women against HIV-1 infection may require a vaccine specifically targeting
mucosal immune responses in the female genital tract (FGT). To achieve this goal,
a much better understanding of the immunology of the FGT is needed. Here we
review the architecture of the immune system of the FGT, recent studies of potential
methods to achieve the goal of mucosal protection in women, including systemic-prime,
mucosal-boost, FGT-tropic vectors and immune response altering adjuvants. Advances in
other fields that enhance our understanding of female genital immune correlates and
the interplay between hormonal and immunological systems may also help to achieve
protection of women from HIV infection.
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INTRODUCTION
The burden of human immunodeficiency virus (HIV) infection
in the twenty-first century falls disproportionately on women,
particularly in the developing world. Women in Sub-Saharan
Africa have, on average, a 60% increased risk of HIV infection
compared with their male counterparts (Magadi, 2011) and now
account for 58% of HIV-infected adults in the region (UNAIDS,
2012a). Despite these statistics little attention has been paid to
developing vaccine candidates that specifically protect the FGT.
The holy grail of HIV prophylactics is a vaccine preventing
acquisition, achieving “sterilizing immunity.” Unfortunately such
vaccines have proven difficult to develop, due to HIV’s numerous
immune evasion strategies and the speed and strength of immune
response required to prevent virus dissemination. Most previous
vaccine strategies have focused on achieving systemic immu-
nity with conventional intramuscular immunization. However,
HIV is arguably a mucosal disease, with acquisition most com-
mon via mucosal routes. The ability of HIV to overcome the
epithelial barrier and innate immune responses, together with
the delayed development of adaptive immune responses, means
that there is a very narrow time-window for protection against
acquisition at the mucosa. Furthermore, systemic vaccines do
not elicit sufficient local immune responses, including secretory
Immunoglobulin A (sIgA) (Baral et al., 2012), to prevent infec-
tion, so it seems likely that a mucosal strategy such as a vaccine
or microbicide, eliciting both systemic and mucosal immune
responses, will be most effective in preventing acquisition. Given
the biological differences between the immunology of the FGT
and other mucosal compartments, a mucosal vaccine specifically
targeting the FGT would seem to be the best way to protect
women against the spread of HIV.
EPIDEMIOLOGY OF HIV-1 INFECTION IN WOMEN
Vaginal heterosexual sex is the most common route of trans-
mission worldwide (Kalichman et al., 2011; UNAIDS, 2012b),
and women are believed to have double the risk of infection
via this route compared to men (Boily et al., 2009). Young
women (aged 15–24) are particularly susceptible, accounting
for 22% of all new infections (Rodriguez-Garcia et al., 2013).
Various factors, both biological and social, may contribute to
the high rates of HIV infection in young women. At a social
level gender biases are common, particularly in developing
countries. The frequency of violence against women combined
with their lower socioeconomic status leads to power imbal-
ances. These relationship dynamics give women little ability
to negotiate safer sexual practices or the use of contracep-
tives; hence women are less able to protect themselves actively
against infection (Stein, 1990). This is compounded by unequal
access to education, with studies suggesting women have con-
sistently poorer knowledge of the benefits of condoms in HIV
prevention (UNAIDS, 2012a). In addition, other female popu-
lations are pivotal in disease spread. Female sex workers con-
tribute heavily to HIV-1 transmission due to their high HIV
prevalence, estimated at 12% worldwide (Baral et al., 2012),
along with increased sexual activity. These factors led to direct
implication of the sex trade in 10% of Ugandan HIV diag-
noses in 2010 (Government of Uganda, 2008). Pregnant women
can transmit HIV during pregnancy, labor or breastfeeding,
and may also be more likely to acquire HIV than their non-
pregnant counterparts (Drake et al., 2014). Effective protection
of women is therefore likely to have a large impact on HIV
transmission to men and children, especially in high prevalence
regions.
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IMMUNITY IN THE FGT
ANATOMY AND IMMUNOLOGICAL STRUCTURE OF THE FGT
The FGT can be divided into two distinct regions: the lower con-
sisting of vulva and vagina, and the upper of ovaries, fallopian
tubes and uterus, including the ectocervix and endocervix. The
vagina was previously thought to be the site of HIV-1 acquisition;
however it is now thought that the cervix, particularly the endo-
cervix and the area between the endocervix and ectocervix known
as the transformation zone, are particularly susceptible to infec-
tion (Nuovo et al., 1993). This is probably due to an abundance of
potential HIV target cells, CD4+ T-cells, macrophages and den-
dritic cells, in this region (Pudney et al., 2005), which separates
the richly colonized lower reproductive tract and the relatively
sterile upper tract. In adolescence, the columnar epithelium of
the endocervix extends down into the ectocervix, a phenomenon
known as cervical ectopy. This exposes a greater area of more sus-
ceptible tissue to potential infection and may contribute to the
high risk of HIV infection in adolescent girls.
Cervico-vaginal fluid (CVF) is secreted throughout the FGT
mucosa and constitutes the first line of mucosal defense: CVF
contains an array of soluble factors including chemokines,
cytokines and anti-microbial peptides, many of which have potent
anti-HIV activity. Intriguingly, the CVF of younger women, par-
ticularly those with cervical ectopy, shows increased levels of pro-
inflammatory cytokines (Hwang et al., 2011). This may further
increase their susceptibility to HIV infection, as inflammation in
the genital tract has been associated with increased HIV infec-
tion risk in several studies (Levinson et al., 2009; Naranbhai et al.,
2012).
The FGT is unique among mucosal surfaces in that it largely
lacks organized lymphoid elements, possessing instead small
numbers of mononuclear cells scattered throughout the sub-
epithelial stroma (Yeaman et al., 1997). This is in marked contrast
to the resident immune system of the intestinal mucosa, which
consists of clearly-defined lymphoid patches, sub-mucosal lym-
phocytes, and a large population of intraepithelial lymphocytes
poised between crypt epithelial cells (Perry et al., 1998). The
absence of a follicular structure means that it is difficult to iden-
tify an FGT immune inductive site, responsible for initiating an
immune response. Therefore, induction of immunity to genital
pathogens is assumed to occur outside the genital tract, followed
by recruitment of re-circulating cells into infected sites through
the common mucosal immune system (CMIS) (Kantele et al.,
1998). There is some evidence that suggests FGT induction sites
may be associated with nasal-associated lymphoid tissue (NALT),
gut-associated lymphoid tissue (GALT), or bronchial-associated
lymphoid tissue (BALT), but none of these preferentially induce
local FGT B cells (Mestecky and Russell, 2000) (see Figure 1 for
details of general inductive and effector sites). An understanding
of the pathways that direct lymphocyte trafficking to the FGT is
essential for the development of mucosal vaccines (Perry et al.,
1998).
MUCOSAL HOMING
In the mouse, T lymphocyte recruitment to the genital mucosa
is directed by the same set of interactions that direct T cells to
systemic sites of inflammation, which are distinct from those
that dictate traffic to the intestinal mucosa. The homing path-
ways defined for the intestinal mucosa are assumed to be relevant
to all mucosal sites, but are not well represented in the genital
tract. This presents yet another area for further investigation if a
successful vaccine is to be developed.
IMMUNOLOGICAL ENDOCRINE INTERPLAY
HORMONAL EFFECTS ON IMMUNE RESPONSES IN THE FGT
An important difference between the FGT and other mucosal
sites is the influence of female hormones. These not only pro-
duce the menstrual cycle, but also affect the immunity of the FGT.
Unfortunately this topic has not been extensively researched and
hence knowledge relating to vaccine design is limited. It is known
that some of the anti-viral proteins in CVF are regulated by
hormone status: for example levels of HBD2 and SLP1, two anti-
HIV peptides, are lower in CVF during ovulation (Keller et al.,
2007). In contrast, oestradiol secretion enhances the secretion
of anti-microbial peptides, whilst simultaneously suppressing the
secretion of pro-inflammatory cytokines and chemokines (Fahey
et al., 2008): these observations would predict lower HIV suscep-
tibility in the first half of the cycle. Macaque studies suggest that
females are more susceptible to simian immunodeficiency virus
(SIV) vaginal challenge during the luteal (progesterone domi-
nant) phase of the menstrual cycle (Vishwanathan et al., 2011).
The luteal phase can be thought of as a time of relative immune
suppression in the FGT in order to optimize conditions for fer-
tilization and implantation. The secretion of mucus, as well as
anti-microbial peptides, by the endocervix also varies during the
menstrual cycle, which may influence susceptibility to infection
(Radtke et al., 2012). These factors suggest that there are distinct
patterns of immune response and differing susceptibility to infec-
tion during the three phases of the menstrual cycle. Although
data from human studies are lacking, it has been proposed that
women have a distinct “window of vulnerability” to HIV infec-
tion in the 7–10 days following ovulation (Wira and Fahey, 2008).
Thus future vaccine andmicrobicide trials need to take account of
the menstrual cycle of female participants in order adequately to
assess protection from and susceptibility to HIV infection.
MUCOSAL TRANSMISSION
INITIAL EVENTS IN HIV-1 INFECTION IN THE FGT
Most of our current understanding of the process of HIVmucosal
transmission comes from animal models and in vitro studies, for
example using cervical explants. There is a welcome trend to
make SIV models more physiological, with lower doses of SIV
used repeatedly in a mucosal challenge. In many previous tri-
als macaques were given high doses of SIV, often intravenously,
which is unlikely to represent the early events of HIV-1 infec-
tion in women (Haase, 2011). It is still not entirely clear where
in the human FGT HIV is most likely to establish primary infec-
tion. Transmission studies by Miller and colleagues showed that
both vagina and cervix could be sites of primary SIV infection in
the SIV/Rhesus macaque model (Miller, 1998). More recent evi-
dence suggests that primary infection takes place predominantly
in the cervix following vaginal SIV exposure in macaques, partic-
ularly the endocervix and transformation zone (junction between
endocervix and ectocervix) (Li et al., 2009a), where the target-cell
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FIGURE 1 | Schematic of the common mucosal immune system (CMIS) relevant to the stimulation of vaccine-induced responses in the female
genital tract.
density [T cells and antigen presenting cells (APCs)] and turnover
is greatest (Li et al., 2009b), and where breaks in the mucosa often
occur (Norvell et al., 1984).
It was initially thought that HIV first infected vaginal APCs
such as macrophages and Langerhans cells, with subsequent
rounds of replication occurring in the draining lymph nodes. This
was thought to be followed by spread to more proximal lymphoid
nodes and finally to the bloodstream and distant lymphoid tissue
(Miller, 1998). Subsequently Zhang et al showed that the first cell
to be infected is the endocervical intraepithelial resting CD4+ T
cell (Zhang et al., 1999). Human cervical explant culture models
confirmed that memory CD4+ T cells were the first infected dur-
ing HIV transmission across the cervical mucosa (Gupta et al.,
2002) (see Figure 2).
Most of our understanding of the very early events following
HIV transmission has come from the macaque model of acute
SIV infection. Even when large amounts of viral RNA are used
in the inoculum, only small foci of tissue-associated viral RNA
are found in the first 3–4 days after infection, consistent with a
limited founder population of infected cells (Haase, 2011). These
clusters of 40–50 infected cells are most consistently found in
the endocervix and transformation zone, and expand locally by
recruitment of susceptible cells. These observations suggest that
there is a critical “window of opportunity” in the first few days
after infection, when a targeted immune response involving virus-
specific antibodies and/or cytotoxic T lymphocytes (CTL), could
control and clear the initial infection before local expansion and
subsequent dissemination into the lymphatics. In macaque stud-
ies, an influx of SIV-specific CTL was identified that the authors
described as generally “too little,” i.e., at too low an effector-
to-target ratio to control the infection, and “too late” (Li et al.,
2009b).
CORRELATES OF HIV IMMUNITY IN THE FGT
It is still not clear what responses a vaccine should elicit for pro-
tection of the FGT against HIV-1, but some valuable insights
have come from studying highly-exposed seronegative subjects
(HESNs). SIgA, the major immunoglobulin class involved in
mucosal immunity, specific for HIV has been found in the gen-
ital fluids of HESN women in several studies (Mazzoli et al., 1997;
Devito et al., 2000a,b, 2002; Belec et al., 2001; Broliden et al.,
2001; Freeman et al., 2006; Tudor et al., 2009) suggesting it may be
important in the protective immune response (Kaul et al., 2001).
Further investigations of the HIV IgA response showed these anti-
bodies were directed toward gp41 and were able to inhibit HIV-1
transcytosis and neutralize virions (Devito et al., 2000a,b; Belec
et al., 2001; Tudor et al., 2009). HIV-1-specific-immunoglobulin
G (IgG) has also been found in the FGT of HESNs (Belec et al.,
2001; Buchacz et al., 2001). However, another group found no
detectable HIV-1 specific vaginal IgG or IgA in a population of
HESNs in the Gambia (Dorrell et al., 2000).
Cellular responses may also contribute to protection against
HIV infection. HIV-specific CD8+ cytotoxic T-lymphocytes
(CTLs) have been detected in the cervical mucosa of HESN sex
workers (Kaul et al., 2000, 2003), where they were enriched rela-
tive to responses detected in blood (Kaul et al., 2000; Iqbal et al.,
2005).
However, others suggest it is not the immune response against
HIV-1 that provides protection, but rather the overall immune
quiescence of the FGT (Card et al., 2012; Lajoie et al., 2012).
This group reported lower levels of pro-inflammatory cytokines
in female HESNs compared to HIV-negative controls (Card et al.,
2013), as well as a lower level of expression of genes crucial for
HIV replication (McLaren et al., 2010; Songok et al., 2012). In
contrast, FGT inflammation is associated with an increased risk
www.frontiersin.org November 2014 | Volume 5 | Article 572 | 3
Rafferty et al. HIV vaccine and women
FIGURE 2 | Crossing the first line of defense, the epithelial mucosa, and targets of HIV infection.
of HIV infection, presumably due to the recruitment of activated
CD4+ T-cells (Cohen, 2004; Freeman et al., 2006).
Given that themain function of the FGT is its role in reproduc-
tion, it is not surprising that immune tolerance is an important
feature of the FGT. Tolerance facilitates fetal implantation in the
uterus and allows commensal organisms to colonize the lower
tract. Whilst this may contribute to protection against genital
infection, tolerance mechanisms, including regulatory T-cells and
TGF-β secretion, must therefore be overcome by an induced
vaccine response, requiring a highly immunogenic preparation.
DESIRABLE ATTRIBUTES OF A MUCOSAL VACCINE
THE NEED FOR A MUCOSAL VACCINE
Timing is of the essence to achieve a protective immune response
against HIV. The response must be sufficiently rapid to stop the
infection before the virus disseminates, by which time it is beyond
control (Haase, 2010). Systemic memory responses are too slow
to prevent HIV infection at the mucosa; instead a large pool of
effector cells at the FGT mucosal surface, ready for immediate
mobilization, is more likely to confer protection. Direct com-
parison of mucosal and systemic vaccination routes has shown
the mucosal route alone can induce mucosal memory popula-
tions of CTLs (Gallichan and Rosenthal, 1996) and high-avidity
CTLs (Ranasinghe and Ramshaw, 2009), matching the CTL pro-
files of HIV controllers (Mothe et al., 2012). Systemic vaccines can
elicit FGT IgG, but in comparison to mucosal vaccines induce lit-
tle or no SIgA, which is produced locally by plasma cells in the
FGT stroma (Nardelli-Haefliger et al., 1999; Pattani et al., 2012).
Despite the dominance of the IgG subtype in the lower FGT,
SIgA has a decisive role in protection, acting as the first defense
against the virus by preventing attachment and hence acquisi-
tion (Neutra and Kozlowski, 2006; Brandtzaeg, 2007). Unlike IgG,
IgA does not activate the complement system and so can be
thought of as anti-inflammatory, important for HIV protection.
The impact of a mucosal response to HIV was practically demon-
strated by the success of the 1% tenofovir microbicide (Abdool
Karim et al., 2010).Mucosal vaccines can also stimulate lymphatic
and systemic immune responses (Belyakov et al., 1998), acting as
a catch-all for virions that pass into the circulation. These fac-
tors suggest a mucosal vaccine specific for the FGT would provide
the immune response most likely to prevent HIV acquisition (see
Figure 3 and Box 1).
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FIGURE 3 | A general schematic of vaccine-related immune cells active at the mucosal interface of the female genital tract.
Box 1 | Challenges in developing mucosal vaccines against HIV infection.
• The gross architecture of the FGT immune system is not typical of other mucosal surfaces—it lacks lymphoid aggregates such as
Peyer’s patches in the gastrointestinal tract, which comprise B and T cell zones and are responsible for immune induction.
• Correlates of protection against HIV at this site are not well understood for various reasons, including difficulty in establishing
appropriate models for studying the HIV-immune system interaction at the mucosal interface.
• Immune tolerance is a feature of the FGT, in view of widespread microbial colonization in its lower tract and the principle function of
the upper tract in reproduction—this impedes the mounting of desirable immune responses to locally administered vaccines.
• Systemic immunization, the commonest route of administration of vaccines, is ineffective in generating protective immunity at the
mucosa - systemic vaccines do not elicit sufficient local immune responses including SIgA.
• Protein antigens are poor immunogens when given mucosally. Instead of response induction, they lead to immunological tolerance
or unresponsiveness known as mucosally-induced tolerance. Consequently, adjuvants are needed to ensure an adequate mucosal
immune response is mounted.
ROUTE OF ADMINISTRATION AND THE DOSING STRATEGY
As described above, no specific induction site has been charac-
terized in the FGT (see Figure 1), although immune responses
can be generated by APCs in the sub-mucosa (Wira and Fahey,
2008). Several possible routes have been investigated including
oral, rectal, vaginal, and intranasal. Intranasal administration
seems to be a promising strategy in terms of immune response
and application. Rhesus macaques showed SIV-specific IgA, IgG
and CTLs in cervico-vaginal washes post intranasal immuniza-
tion with SIV-p55gag with cholera toxin adjuvant (Imaoka et al.,
1998). A study in human volunteers also showed an increase
in vaginal cholera toxin B (CTB)-specific IgA and IgG with a
strong systemic response following intranasal-immunization with
CTB subunit (Bergquist et al., 1997). However, a Phase 1 trial
of an intranasal HIV-1 vaccine using recombinant HIV-1-gp160
yielded no antibodies in serum or secretory fluids (Pialoux et al.,
2008).
It may be better to use a combined prime-boost strategy
to elicit FGT immunity. This can, however, be complex as
the vaccine response is affected by both the route and the
timing of immunization, particularly the interval between the
prime and the boost. Rhesus Macaques were immunized with
simian-HIV-SF162P3 P1 and recombinant gp41 subunit anti-
gens grafted onto virosomes delivered first intramuscularly (IM)
then boosted with intranasal (IN) application (Bomsel et al.,
2011). Four of five macaques in the IM/IN group were fully
protected against 13 vaginal SHIV challenges delivered over 9
weeks. The other macaques only showed transient infection while
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none seroconverted to p27gag-SIV. In contrast, only one of six
macaques given just the intramuscular formulation was fully pro-
tected. All placebo immunized animals seroconverted. Protected
animals showed cervicovaginal antigen-specific IgA which inhib-
ited HIV-1 transcytosis and IgG with neutralizing or antibody-
dependent cytotoxicity effects. CTLs were not assessed. Some
cross-clade transcytosis-inhibition was found in the IM/IN group,
suggesting the generation of more broadly neutralizing antibod-
ies. The animals lacked neutralizing antibodies in serum, further
emphasizing the importance of a mucosal response for HIV
protection.
A recent phase I placebo-controlled trial tested a virosome
harboring surface HIV-1 gp41-derived P1 lipidated peptides
delivered as an intramuscular prime, then by intranasal boost
(Leroux-Roels et al., 2013). The vaccine was safe and well tol-
erated. P1-specific serum IgG and IgA were induced in all par-
ticipants receiving the high dose of vaccine. Analysis did not
reveal a statistically significant increase in mucosal P1-specifc
IgA, despite being detected in 63 and 43% of the low and high
dose participants respectively. However, there was an unexpect-
edly high pre-immune vaginal reactivity toward the P1 antigen,
which may have skewed the results. IgA expression is influenced
by hormonal changes so sampling during different phases of
the menstrual cycle may explain these findings. Vaginal and rec-
tal IgG did increase significantly over the weeks of vaccination
for both the high and the low dose groups. These vaginal anti-
bodies were further investigated and were shown to possess the
ability to inhibit HIV-1 transcytosis. This result shows promise,
demonstrating both the safety and immunogenicity of mucosal
vaccines.
A study looking at HSV-2 infection used a novel prime-boost
strategy known as “prime-pull,” which could be extrapolated
to an HIV vaccine (Shin and Iwasaki, 2012). The “prime-pull”
technique involves the mucosal application of chemokines after
immunization to recruit primed cells to the mucosa. Mice were
immunized systemically, then chemokines CXCL9 and CXCL10
were applied directly to the vaginal mucosa. CTLs were recruited
to the FGT and established a long-term population of memory
CD8+ T cells. CD4+ T cells were initially recruited to the FGT but
not retained there long-term. The initial CD4+ T-cell influx could
potentially increase HIV risk, but after the effector phase these
cells withdrew, so overall the risk is deemed negligible. In addi-
tion, no markers of inflammation were found, and the strategy
led to complete protection from vaginal HSV-2 infection.
Following this promising result the “prime-pull” technique
was recently adapted to HIV. Mice were immunized intranasally
with HIV-1-gp140 and then either the cytokine CCL28 or the
toll-like receptor 4 ligand (TLR4) MPLA was administered to
the vaginal mucosa (Tregoning et al., 2013). The application
of CCL28 post-intranasal vaccine did not increase vaginal B
cells or antibodies; however MPLA application caused signifi-
cant increases in HIV-1 specific vaginal IgA and serum IgG and
IgA. The authors concede that, as homing mechanisms in the
urogenital tract are not well understood, CCL28 may not have
been the best cytokine to use, and suggest that other chemokines
involved in B-cell recruitment should be tested. It may be that
a single cytokine is insufficient and several acting in concert
would provide a better “pull” toward the urogenital tract. On the
other hand the success of MPLA adds another dimension to this
“prime-pull” strategy; different TLR agonists should also now be
investigated.
ADJUVANTS
As seen with the “prime-pull” strategy described above, most
vaccines require an adjuvant to boost the immunogenicity of
the construct. Adjuvants are substances that possess the biolog-
ical capacity to enhance, prolong or accelerate the quality of
specific immune responses to vaccine antigens. With regards to
mucosal vaccines, adjuvants can be broadly classified into those
that play an immunostimulatory role and those that facilitate
vaccine delivery for the induction of protective immunity via the
CMIS (Yuki and Kiyono, 2003).
Few adjuvant studies have focused on boosting mucosal HIV-
specific immunity. Chemokines and cytokines are widely thought
to be the most effective adjuvants for HIV-1 vaccines. When
CCL28 was used to adjuvant an HIV-1IIIB virus like particle
(VLP) construct, enhanced neutralizing capabilities against HIV-
1 clade B laboratory isolates and an HIV-1 clade C primary
isolate were found in vaginal secretions and sera of mice (Rainone
et al., 2011). Increased env-specific interferon gamma (IFN-γ)
and interleukin (IL)-45 were also seen, with increased serum IgA,
both non-specific and specific for HIV-1. More recently, mice
were immunized either IM or IN with HIV-1 gp140 co-delivered
with plasmid CCL19 or CCL28 (Hu et al., 2013). Both IM and
IN protocols enhanced serum IgG responses, and both cytokines
enhanced vaginal IgG and IgA responses, but only when given via
the IN route. The vaginal antibodies showed neutralizing activity
against both homologous and heterologous HIV-1.
A novel approach to using cytokines as adjuvants employed
soluble IL-13 receptors to antagonize the IL-13 response
(Ranasinghe et al., 2013). Recombinant poxviruses that co-
expressed HIV-1-gag/pol with IL-13Rα2 soluble receptors were
given via intranasal-prime, intramuscular-boost to female mice.
The transient blockade of IL-13 resulted in the generation of high-
avidity CTLs in the iliac and genito-rectal nodes (which drain the
FGT), which were not found in the control protocol without sol-
uble IL-13Rα2: high-avidity CTLs were more protective, shown
by greater protection following an intranasal challenge with gag-
expressing influenza in the IL-13Rα2 group. The stimulation of
high-avidity CTLs matches the CTL profiles of HIV controllers
(Mothe et al., 2012). This study presents an interesting alternative
to the conventional addition of cytokines. Potentially a mixture
of addition and blockade of cytokine pathways will generate a
suitable immune response in the FGT.
FGT TROPIC VECTORS
Given the mucosal site of HIV acquisition, effective vectors
should exhibit mucosal tropism, ideally specific for the FGT.
Adenovirus, a commonly used vector, targets the mucosa but
is not FGT-specific: this may contribute to its lack of success
in clinical trials to prevent HIV infection. There is controversy
surrounding the use of adenovirus as a vector after the STEP
trial (HVTN502/Merck023), the first clinical trial to examine an
HIV prophylactic vaccine using adenovirus as a vector, suggested
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that adenovirus priming may actually increase the risk of HIV
infection (Buchbinder et al., 2008).
Human papillomavirus (HPV) is a FGT tropic virus that
infects cervicovaginal keratinocytes, lying senescent for long
periods of time. A recent study in Cynomolgus and Rhesus
Macaques used HPV pseudovirosomes to deliver SIV-Gag-DNA
(Gordon et al., 2012). Gag-specific IgA, IgG and CD4/8+ T cell
responses were found in the serum and vaginal tract, which
rapidly expanded following intravaginal SIV exposure, suggest-
ing the formation of memory populations. However limitations
of this study were that only low levels of vaginal IgG and IgA were
induced, and the vaccine led to a substantial CD4+ T cell response
that could increase HIV susceptibility: there was no protection
against vaginal SIV challenge. Furthermore, unattenuated HPV
has been shown to increase CXCL8 levels, potentially increasing
susceptibility to HIV-1 in cervical tissues and upregulating HIV-1
proliferation (Narimatsu et al., 2005).
These are early days in mucosal targeting of vaccines: with sub-
sequent testing and refining, better results may be achieved. Other
sexually transmitted disease (STD) vectors such as HSV-2 could
also be tested as vectors. HSV-1 has been used as a vector in mice
(Parker et al., 2007), using an HSV-1 vector expressing the HIV-
1 gag gene for intraperitoneal immunization. Strong gag-specific
CD8+ responses were elicited (Parker et al., 2007) which persisted
9 months post-immunization. HSV-2 is closely related to HSV-1,
but is acquired through the genital mucosa suggesting it may be a
more appropriate HIV vaccine vector. However, further research
is needed to improve immune responses and reduce potentially
harmful mucosal inflammation.
FUTURE DIRECTIONS
Despite the possibilities highlighted in these studies, several fac-
tors must be addressed to improve the development of an effective
HIV vaccine. We strongly recommend that immune responses in
the FGT should be measured as an integral part of every HIV
vaccine trial. Even though precise correlates of immunity are not
yet known, it seems reasonable to assume that local immune
responses to HIV in the FGT will play an important part in pro-
tection against sexual acquisition. Ensuring that FGT responses
are always measured provides a timely reminder of the site where
most HIV infections in the world are acquired, and should inform
future trials and vaccine design. Correlates of FGT inflammation
should also be investigated to ensure a vaccine does not increase
HIV susceptibility. A focus on FGT responses requires a distinct
agenda from the outset so that a laboratory science program is
incorporated and prioritized within the parent clinical trial pro-
tocol. It is also important to study participants with breakthrough
infections, and collect and store relevant, appropriate, and appro-
priately timed biological specimens, collected as close as possible
to the estimated time of infection, (Sibeko and Makvandi-Nejad,
2013).
Our lack of knowledge in key aspects of FGT immunol-
ogy remains a major problem for mucosal vaccine development.
Characterization of FGT homing pathways would greatly improve
mucosal vaccine design, as would clear evidence of which com-
partment in the human FGT is most susceptible to HIV infection.
HIV predominantly affects women in developing countries, and
therefore for maximal public health benefit new vaccines should
be cheap, store well, and preferably not require administration by
medical practitioners.
Despite having a significant impact on the immunology of the
FGT, the changing levels of estrogen and progesterone throughout
the menstrual cycle have rarely been considered in natural history
or vaccine studies (Hickey et al., 2011). A better understanding of
the immunological milieu in different menstrual phases may sug-
gest a specific point of the cycle when vaccination would be most
beneficial. Previous studies suggest that intravaginal vaccination
is most effective in women during the follicular phase of the
cycle (Kozlowski et al., 2002). The effects of hormones on other
mucosal routes have not yet been characterized. The cycle stage
should therefore be an important consideration in vaccine trials,
and vaccines should be tested during different hormonal stages
to assess the most effective timing of administration. Adolescence
is an important period when major hormonal fluctuations occur.
The HIV-1 incidence in the 15–24 year age group is twice as high
in women compared to men (UNAIDS, 2012a), highlighting the
importance and challenges of vaccine efficacy in this vulnerable
group.
Differential immune responses for adults and adolescents
against HSV-2 and E. Coli suggest that correlates of mucosal
immunity may differ substantially in different age-groups
(Madan et al., 2012). It may therefore be necessary to look sys-
tematically at different populations and to include adolescents in
future vaccine trials. Furthermore, substantial hormonal fluctua-
tions also occur during pregnancy and with the use of hormonal
contraceptives. In the future, vaccine assessment should extend
to these groups in clinical trials to ensure optimal protection of
women at different stages of life.
CONCLUSIONS
The dynamics of HIV infection are changing, with more women
infected than in previous years and at younger ages than their
male counterparts. This trend probably reflects a combination
of socioeconomic and biological factors. Preventing infection in
women will have a major impact on HIV incidence in their part-
ners and children. A vaccine specifically targeting the FGT may
be needed to induce an immune response that is able to contain
HIV prior to dissemination. As mucosal vaccines induce SIgA and
mucosal CTLmemory responses more successfully than their sys-
temic counterparts, a mucosal vaccine specifically targeting the
FGT appears to be the best option for preventing HIV acquisition.
Several strategies look promising, with systemic-prime, mucosal-
boost, FGT tropic vectors, and adjuvants tailoring the immune
response to the FGT all yielding encouraging results in animal
models. However, much more must be done: future vaccine trials
must put more emphasis on the immune responses of the FGT
and consider hormonal effects on mucosal immunity from the
outset. Further research on mucosal vaccines specifically target-
ing these issues may finally yield the protective vaccine needed
to protect women and the wider population from the spread
of HIV.
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